A multi-site, open-label surgical sub-study of the Phase 1-2 protocol ST101 to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 in patients with recurrent and newly diagnosed GBM
Latest Information Update: 16 Aug 2022
At a glance
- Drugs Lucicebtide (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; Proof of concept
- Sponsors Sapience Therapeutics
Most Recent Events
- 16 Aug 2022 New trial record